Crameri R, Lidholm J, Grönlund H, Stüber D, Blaser K, Menz G
Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland.
Clin Exp Allergy. 1996 Dec;26(12):1411-9.
We report the results of a study comparing the recombinant Aspergillus fumigatus allergen 1 (rAsp f I) to commercial A. fumigatus extracts in serological assays. Pharmacia CAP System and skin tests.
The study was designed to test the feasibility of using recombinant allergens in an automated serology system for determination of allergen-specific IgE.
Patients with allergic bronchopulmonary aspergillosis (ABPA), asthmatics with A. fumigatus allergy and control subjects, who included allergic asthmatics without allergy to A. fumigatus and healthy subjects, were investigated. All subjects were characterized with respect to their total IgE level, radio allergosorbent test to A. fumigatus and skin test reactivity to both commercial A. fumigatus extracts and recombinant rAsp f I protein.
All patients with ABPA (n = 30) showed positive skin test reactions with commercial A. fumigatus extracts, and 24 were sensitized to rAsp f I by the same criterion. The 10 patients with asthma and A. fumigatus allergy showed positive skin reactions to at least one commercial extract, and five reacted to rAsp f I. All control subjects (n = 19) scored negatively in skin tests to A. fumigatus extracts and rAsp f I and showed no detectable rAsp f I-specific IgE. ImmunoCAP carrying immobilized rAsp f I were evaluated using sera from all individuals described and the results compared with those obtained with the rAsp f I-specific ELISA for IgE. The data obtained with the two rAsp f I-specific detection systems correlated closely (r = 0.997) and were in perfect agreement with the skin test results.
The data show that rAsp f I can be used as immobilized allergen in the Pharmacia CAP System indicating the feasibility of using recombinant allergens for an automated serological diagnosis of allergic diseases. However, every recombinant allergen needs to be evaluated individually for its performance if applied to a new diagnostic technology.
我们报告了一项在血清学检测、Pharmacia CAP系统和皮肤试验中，比较重组烟曲霉变应原1（rAsp f I）与市售烟曲霉提取物的研究结果。
本研究旨在测试在自动化血清学系统中使用重组变应原测定变应原特异性IgE的可行性。
对患有过敏性支气管肺曲霉病（ABPA）的患者、对烟曲霉过敏的哮喘患者以及对照受试者进行了研究，对照受试者包括对烟曲霉无过敏的过敏性哮喘患者和健康受试者。对所有受试者的总IgE水平、针对烟曲霉的放射性变应原吸附试验以及对市售烟曲霉提取物和重组rAsp f I蛋白的皮肤试验反应性进行了表征。
所有ABPA患者（n = 30）对市售烟曲霉提取物的皮肤试验反应均为阳性，按照相同标准，2４例对rAsp f I致敏。10例患有哮喘且对烟曲霉过敏的患者对至少一种市售提取物的皮肤反应呈阳性，5例对rAsp f I有反应。所有对照受试者（n = 19）对烟曲霉提取物和rAsp f I的皮肤试验结果均为阴性，且未检测到rAsp f I特异性IgE。使用所述所有个体的血清对固定有rAsp f I的免疫CAP进行了评估，并将结果与用rAsp f I特异性IgE ELISA获得的结果进行比较。用两种rAsp f I特异性检测系统获得的数据密切相关（r = 0.997），且与皮肤试验结果完全一致。
数据表明，rAsp f I可作为固定化变应原用于Pharmacia CAP系统，这表明使用重组变应原进行过敏性疾病自动化血清学诊断具有可行性。然而，如果将每种重组变应原应用于新的诊断技术，则需要对其性能进行单独评估。
